Materials and Methods: 23 eyes of 16 patients with ocular allergy to BBFC were enrolled to this prospective study. Demographic and clinical characteristics were evaluated. Schirmer I test,Oxford corneal stain scale, tear break-up time, and Ocular Surface Disease Index (OSDI) score were performed to evaluate ocular surface disease. QoL was assessed with the Turkish version of the National Eye Institute Visual-Function Questionnaire (NEIVFQ-25 TR).

Results: Duration of BBFC treatment was 6.1±3.3 months and duration of allergy symptoms was 3.6±2.4 months. Mean OSDI score was 34.48±26 indicating severe dry eye disease. There was a positive correlation between OSDI scores and duration of glaucoma (p=0.0001, R:0.89, CI:0.3-0.6) and duration of BBFC treatment. (p=0.02, R:0.58, CI:-8.2- -0.7) There was no correlation between mean duration of allergy symptoms and OSDI scores. (P=0.14 R:0.38, CI:-9.1- -1.5) The development of BBFC ocular allergy caused a decrease in the results of all NEI VFQ-25/TR subscales except driving and color vision. Negative correlation was found between OSDI and subscales of general vision (p=0.04 R=-0.509, CI=-0.9 - -0.35) and vision specific social functioning (p=0.007 R=-0.64, CI=-1.5- -0.3), driving (p=0.01 R=-0.82, CI=-2.7- -0.49) and color vision. (p=0.02 R=-0.55, CI=-1.9- -0.08) There was a positive correlation between OSDI and subscales of ocular pain. (p=0.01 R=0.61, CI=-0.9- -0.19).

Conclusion: Development of ocular allergy to BBFC has a quantitatively negative effect on the ocular surface and QoL. Keywords : Brinzolamide brimonidine fixed combination, Glaucoma, ocular allergy, Ocular surface disease index, Quality of life